Annual CFF
$332.11 M
+$162.28 M+95.56%
December 31, 2024
Summary
- As of March 12, 2025, OCUL annual cash flow from financing activities is $332.11 million, with the most recent change of +$162.28 million (+95.56%) on December 31, 2024.
- During the last 3 years, OCUL annual CFF has risen by +$329.26 million (+11548.90%).
- OCUL annual CFF is now at all-time high.
Performance
OCUL Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$4.51 M
+$335.00 K+8.02%
December 31, 2024
Summary
- As of March 12, 2025, OCUL quarterly cash flow from financing activities is $4.51 million, with the most recent change of +$335.00 thousand (+8.02%) on December 31, 2024.
- Over the past year, OCUL quarterly CFF has increased by +$335.00 thousand (+8.02%).
- OCUL quarterly CFF is now -98.60% below its all-time high of $321.22 million, reached on March 31, 2024.
Performance
OCUL Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$332.11 M
-$103.66 M-23.79%
December 31, 2024
Summary
- As of March 12, 2025, OCUL TTM cash flow from financing activities is $332.11 million, with the most recent change of -$103.66 million (-23.79%) on December 31, 2024.
- Over the past year, OCUL TTM CFF has dropped by -$103.66 million (-23.79%).
- OCUL TTM CFF is now -32.36% below its all-time high of $490.97 million, reached on March 31, 2024.
Performance
OCUL TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
OCUL Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +95.6% | +8.0% | -23.8% |
| 3 y3 years | +10000.0% | +576.6% | +10000.0% |
| 5 y5 years | +340.8% | -50.4% | +340.8% |
OCUL Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -98.6% | +5685.9% | -32.4% | >+9999.0% |
| 5 y | 5-year | at high | >+9999.0% | -98.6% | +488.4% | -32.4% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -98.6% | +488.4% | -32.4% | >+9999.0% |
Ocular Therapeutix Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $332.11 M(+95.6%) | $4.51 M(+8.0%) | $332.11 M(-23.8%) |
| Sep 2024 | - | $4.18 M(+90.3%) | $435.77 M(-9.9%) |
| Jun 2024 | - | $2.20 M(-99.3%) | $483.52 M(-1.5%) |
| Mar 2024 | - | $321.22 M(+197.0%) | $490.97 M(+189.1%) |
| Dec 2023 | $169.83 M(>+9900.0%) | $108.17 M(+108.3%) | $169.83 M(+173.4%) |
| Sep 2023 | - | $51.94 M(+438.5%) | $62.12 M(+488.5%) |
| Jun 2023 | - | $9.64 M(>+9900.0%) | $10.55 M(+652.3%) |
| Mar 2023 | - | $78.00 K(-83.0%) | $1.40 M(-3.5%) |
| Dec 2022 | $1.45 M(-49.0%) | $458.00 K(+22.5%) | $1.45 M(-12.6%) |
| Sep 2022 | - | $374.00 K(-24.1%) | $1.66 M(-15.5%) |
| Jun 2022 | - | $493.00 K(+282.2%) | $1.97 M(-52.5%) |
| Mar 2022 | - | $129.00 K(-80.7%) | $4.14 M(+45.3%) |
| Dec 2021 | $2.85 M(-98.7%) | $667.00 K(-1.8%) | $2.85 M(-98.3%) |
| Sep 2021 | - | $679.00 K(-74.5%) | $166.10 M(+0.3%) |
| Jun 2021 | - | $2.67 M(-329.5%) | $165.64 M(-22.6%) |
| Mar 2021 | - | -$1.16 M(-100.7%) | $214.03 M(-6.1%) |
| Dec 2020 | $228.01 M(+202.6%) | $163.91 M(>+9900.0%) | $228.01 M(+211.5%) |
| Sep 2020 | - | $220.00 K(-99.6%) | $73.19 M(-20.1%) |
| Jun 2020 | - | $51.06 M(+298.4%) | $91.58 M(+99.7%) |
| Mar 2020 | - | $12.82 M(+41.0%) | $45.86 M(-39.1%) |
| Dec 2019 | $75.34 M(+9.8%) | $9.09 M(-51.2%) | $75.34 M(-8.8%) |
| Sep 2019 | - | $18.61 M(+248.7%) | $82.58 M(+9.6%) |
| Jun 2019 | - | $5.34 M(-87.4%) | $75.34 M(-1.8%) |
| Mar 2019 | - | $42.30 M(+159.1%) | $76.71 M(+11.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $68.64 M(+114.4%) | $16.33 M(+43.6%) | $68.64 M(+28.3%) |
| Sep 2018 | - | $11.37 M(+69.4%) | $53.52 M(+22.5%) |
| Jun 2018 | - | $6.71 M(-80.4%) | $43.67 M(+15.7%) |
| Mar 2018 | - | $34.23 M(+2738.1%) | $37.76 M(+18.0%) |
| Dec 2017 | $32.01 M(+5371.5%) | $1.21 M(-21.1%) | $32.01 M(+1.6%) |
| Sep 2017 | - | $1.53 M(+92.1%) | $31.50 M(+4.8%) |
| Jun 2017 | - | $796.00 K(-97.2%) | $30.04 M(+2.7%) |
| Mar 2017 | - | $28.48 M(+4009.2%) | $29.25 M(+4900.2%) |
| Dec 2016 | $585.00 K(-99.1%) | $693.00 K(+788.5%) | $585.00 K(+192.5%) |
| Sep 2016 | - | $78.00 K(+2500.0%) | $200.00 K(-353.2%) |
| Jun 2016 | - | $3000.00(-101.6%) | -$79.00 K(-100.1%) |
| Mar 2016 | - | -$189.00 K(-161.4%) | $65.65 M(-0.1%) |
| Dec 2015 | $65.70 M(-16.8%) | $308.00 K(-253.2%) | $65.70 M(+0.6%) |
| Sep 2015 | - | -$201.00 K(-100.3%) | $65.29 M(-50.9%) |
| Jun 2015 | - | $65.73 M(<-9900.0%) | $133.04 M(+67.8%) |
| Mar 2015 | - | -$137.00 K(+29.2%) | $79.27 M(+0.4%) |
| Dec 2014 | $78.97 M(+1081.7%) | -$106.00 K(-100.2%) | $78.97 M(+0.4%) |
| Sep 2014 | - | $67.56 M(+465.1%) | $78.63 M(+640.5%) |
| Jun 2014 | - | $11.95 M(-2860.7%) | $10.62 M(+58.4%) |
| Mar 2014 | - | -$433.00 K(-3.6%) | $6.71 M(+0.3%) |
| Dec 2013 | $6.68 M(-75.5%) | -$449.00 K(-1.1%) | $6.68 M(-6.3%) |
| Sep 2013 | - | -$454.00 K(-105.6%) | $7.13 M(-6.0%) |
| Jun 2013 | - | $8.04 M(-1867.3%) | $7.59 M(-1767.3%) |
| Mar 2013 | - | -$455.00 K | -$455.00 K |
| Dec 2012 | $27.30 M | - | - |
FAQ
- What is Ocular Therapeutix annual cash flow from financing activities?
- What is the all time high annual CFF for Ocular Therapeutix?
- What is Ocular Therapeutix annual CFF year-on-year change?
- What is Ocular Therapeutix quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Ocular Therapeutix?
- What is Ocular Therapeutix quarterly CFF year-on-year change?
- What is Ocular Therapeutix TTM cash flow from financing activities?
- What is the all time high TTM CFF for Ocular Therapeutix?
- What is Ocular Therapeutix TTM CFF year-on-year change?
What is Ocular Therapeutix annual cash flow from financing activities?
The current annual CFF of OCUL is $332.11 M
What is the all time high annual CFF for Ocular Therapeutix?
Ocular Therapeutix all-time high annual cash flow from financing activities is $332.11 M
What is Ocular Therapeutix annual CFF year-on-year change?
Over the past year, OCUL annual cash flow from financing activities has changed by +$162.28 M (+95.56%)
What is Ocular Therapeutix quarterly cash flow from financing activities?
The current quarterly CFF of OCUL is $4.51 M
What is the all time high quarterly CFF for Ocular Therapeutix?
Ocular Therapeutix all-time high quarterly cash flow from financing activities is $321.22 M
What is Ocular Therapeutix quarterly CFF year-on-year change?
Over the past year, OCUL quarterly cash flow from financing activities has changed by +$335.00 K (+8.02%)
What is Ocular Therapeutix TTM cash flow from financing activities?
The current TTM CFF of OCUL is $332.11 M
What is the all time high TTM CFF for Ocular Therapeutix?
Ocular Therapeutix all-time high TTM cash flow from financing activities is $490.97 M
What is Ocular Therapeutix TTM CFF year-on-year change?
Over the past year, OCUL TTM cash flow from financing activities has changed by -$103.66 M (-23.79%)